



January 26, 2026

PDRadiopharma Inc.

PDRadiopharma Launches Solar Power Generation at Chiba Site – Advancing ESG Management through the Use of Renewable Energy –

TOKYO, JAPAN – January 26, 2026 - PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan) announced today that it has started operation of a solar power generation system at its Chiba site as part of its commitment to environmental sustainability and ESG-driven management.

By utilizing previously unused land within the site, this initiative enables on-site generation of renewable energy, contributing to the reduction of CO₂ emissions associated with electricity consumption while also optimizing energy costs. As a company responsible for the manufacturing and stable supply of radiopharmaceuticals, ensuring sustainable and environmentally responsible operations is an important element in supporting long-term healthcare infrastructure.

Together with our parent company, PeptiDream Inc., PDRadiopharma promotes management that places strong emphasis on ESG (Environmental, Social, and Governance) principles.

PDRadiopharma remains committed not only to contributing to patients and the healthcare community through radiopharmaceuticals, but also to contributing to the realization of a sustainable society through responsible corporate activities. Going forward, we will continue to place sustainability at the core of our management and pursue responsible corporate activities.

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: s-info-hq@pdradiopharma.com